Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients With Molecularly-Selected Solid Tumors (ComBET)

This study is testing whether a combination of two drugs, ZEN-3694 and talazoparib, can help stop or shrink advanced solid tumors. These medications work by blocking proteins that cancer cells need to grow and preventing them from repairing their own DNA, which may cause the cancer cells to die.

This trial is for patients with advanced cancer that has spread or cannot be removed by surgery and is no longer responding to standard treatments. You must have specific genetic mutations in your tumor, such as BRCA1 or BRCA2, and have already been treated with a PARP inhibitor.

Participants will take the study medications and undergo regular health check-ups. You will also provide blood and tissue samples so researchers can study your cancer’s genetic makeup and track how well the treatment is working through regular medical scans.

The study is currently recruiting patients at medical centers in Duarte, Irvine, and La Jolla, California. If you are interested, your care team can help you determine if your specific genetic profile fits the study requirements.